Peter Emtage, Ph.D. is the Global Head of Cell Therapy Research, at Kite Pharma a Gilead Company. Peter, was previously CSO at Cell Design Labs (CDL), before CDL was acquired by Kite. Prior to joining CDL, he held senior positions at Intrexon, Medimmune and Femta Pharmaceuticals. Peter is an immunologist by training and over the past 20 years has focused on developing drugs to modulate the immune response in humans. His work in oncology, autoimmunity and infectious disease has included the utilization of viral and non-viral delivery systems, chimeric antigen receptor and TCR adoptive T cell modalities, and monoclonal antibody development. His career started with a post-doctoral fellowship at the National Institutes of Health followed by his role as Research Scientist at Aventis Pasteur and then Instructor in Medicine at Harvard Medical School.